CMS Open Payments · Program Year 2024
Zak Ortho
Zak Ortho reported $11,421.32 across General Payments, Research, and Ownership to 116 physicians and teaching hospitals across 116 transactions.
- $11.4K
- All-tracks total
- 116
- Transactions
- 116
- Recipients
- #1627
- of 1,925 companies
Zak Ortho reported $11,421.32 across all CMS Open Payments tracks (General + Research + Ownership) to 116 physicians and teaching hospitals in Program Year 2024 - ranking #1627 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $11,421.32, averaging $98.46 per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer zak-ortho Zak Ortho
$11.4K · #1627/1,925 · 0.0% industry · PY2024
- TOT $11.4K
- RANK #1627
- SHARE 0.0%
- TXN 116
- RCP 116
- CAT 2
- GEN $11.4K
- TOP1 9.9%
- PY 2024
Volume peers
Nearest volume peer: Maxx Health Inc ($11.5K)
Zak Ortho sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
What the Data Shows for Zak Ortho
Rank #1627 of 1,925 companies in CMS Open Payments for 2024 belongs to Zak Ortho, which reported $11,421.32 across 116 transactions to 116 recipients - a comparatively small 0.0% slice of all industry payments reported nationwide for the year. Averages work out to $98.46 per transaction and $98.46 per recipient.
42 transactions worth $7.6K make "Travel and Lodging" the top general-payment category in the 2-category breakdown below, 66.7% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Travel and Lodging" leads Zak Ortho's 2-category general-payment breakdown at $7.6K, 66.7% of the reported total.
How Zak Ortho divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Travel and Lodging | $7.6K | 42 | 66.7% |
| Food and Beverage | $3.8K | 74 | 33.3% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $4,895.55 (42.9%) of $11,421.32 in this company's General Payments records across 37 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Zak Ortho
The five named recipients with the highest reported General Payments from this company
- 1
Patrick O'callaghan
$1,129.68 across 7 reported transactions
- 2
Matthew Karek
$1,096.70 across 6 reported transactions
- 3
Alex Flach
$913.08 across 15 reported transactions
- 4
Joshua Veenstra
$888.04 across 12 reported transactions
- 5
Amanda Wrozek
$868.05 across 5 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Zak Ortho's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Zak Ortho.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Zak Ortho.
Showing 6 of 1,924 companies with CMS-reported payment data.
Xenco Medical LLC
Biolase MG LLC
Biobeat USA Inc.
Greiner Bio-One North America, Inc.
EnableCV Inc.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.